Favorable Outcomes of Chinese HCV-Related Cirrhotic Patients with Sustained Virological Response after Pegylated Interferon Plus Ribavirin Treatment
Joint Authors
Gao, Zhiliang
Zhang, Geng-lin
Zhang, Ting
Zhang, Xiao-hong
Zhao, Zhixin
Lin, Chao-shuang
Chen, You-ming
Cai, Qing-xian
Source
Issue
Vol. 2017, Issue 2017 (31 Dec. 2017), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2017-01-23
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
Few studies have conducted follow-up investigations of the clinical course in HCV-related cirrhotic patients who achieved a sustained virological response (SVR) with pegylated interferon plus ribavirin treatment (PegIFN + RBV).
We investigated the clinical course and laboratory data in a prospective cohort study enrolling HCV-related cirrhotic patients who received PegIFN + RBV between August 2008 and July 2013 in China.
Complete blood counts, liver function tests, and HCV-RNA were serially examined.
Liver-related complications were recorded.
To detect hepatocellular carcinoma (HCC), alpha-fetoprotein assays, and ultrasound scans were repeated at 6-month intervals.
Twenty-five patients were enrolled, including 8 patients with decompensation events before treatment.
Eighteen patients achieved SVR with a mean follow-up period of 25.78 months.
During the follow-up period, only one patient exhibited HCV-RNA positivity and no decompensation events were detected, but 4 patients developed HCC after SVR.
APRI decreased more in patients with SVR than in patients with non-SVR (median, −1.33 versus 0.86, P<0.001).
The albumin levels and platelet counts significantly increased during the follow-up period after SVR (44.27±4.09 versus 42.63±4.37, P=0.037 and 173.89±87.36 versus 160.11±77.97, P=0.047).
These data indicated that HCV-related cirrhotic patients with SVR after PegIFN + RBV may have a favorable clinical course and improvements in laboratory data.
Moreover, HCC should be monitored.
American Psychological Association (APA)
Zhang, Geng-lin& Chen, You-ming& Zhang, Ting& Cai, Qing-xian& Zhang, Xiao-hong& Zhao, Zhixin…[et al.]. 2017. Favorable Outcomes of Chinese HCV-Related Cirrhotic Patients with Sustained Virological Response after Pegylated Interferon Plus Ribavirin Treatment. BioMed Research International،Vol. 2017, no. 2017, pp.1-8.
https://search.emarefa.net/detail/BIM-1138889
Modern Language Association (MLA)
Zhang, Geng-lin…[et al.]. Favorable Outcomes of Chinese HCV-Related Cirrhotic Patients with Sustained Virological Response after Pegylated Interferon Plus Ribavirin Treatment. BioMed Research International No. 2017 (2017), pp.1-8.
https://search.emarefa.net/detail/BIM-1138889
American Medical Association (AMA)
Zhang, Geng-lin& Chen, You-ming& Zhang, Ting& Cai, Qing-xian& Zhang, Xiao-hong& Zhao, Zhixin…[et al.]. Favorable Outcomes of Chinese HCV-Related Cirrhotic Patients with Sustained Virological Response after Pegylated Interferon Plus Ribavirin Treatment. BioMed Research International. 2017. Vol. 2017, no. 2017, pp.1-8.
https://search.emarefa.net/detail/BIM-1138889
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1138889